Fumaric acid esters (FAE) are chemical compounds derived
were developed containing dimethylfumarate(DMF) and from the unsaturated dicarbonic acid, fumaric acid. Fumaric salts of monoethylfumarate (MEF) as the main ingredients. acid is a white crystalline powder with a characteristic These were used in thousands of patients in different acidic taste. It is used as a food additive and is commonly European countries including Germany, Switzerland and found as flavoring agent in cakes and sweets. Fumaric
The Netherlands. In 1994, Fumaderm ® , an enteric-coated acid is poorly absorbed and believed to pass through tablet containing DMF and calcium, magnesium and zinc the body without causing any effects. However, esters salts of MEF was approved for the treatment of psoriasis in of fumaric acid (FAEs), such as monoethylfumarate(MEF), Germany and since then has become the most commonly monomethylfumarate (MMF), diethylfumarate (DEF) and used systemic therapy in this country. [2] DMF is rapidly dimethylfumarate(DMF) are potent chemicals and have metabolized to monomethyl fumarate (MMF) which, ABSTRACT been used in the treatment of psoriasis in European countries for over 30 years.
The use of FAEs in the treatment of psoriasis was first introduced in the late 1950s by a German chemist named Schweckendiek. A 'fumaric acid' protocol for psoriasis was introduced that proposed the use of FAEs as oral and topical treatment (ointment and bathing solution). [1] In the 1980s, more standardized oral preparations of FAEs together with DMF, is regarded as the main bioactive metabolite.
Although data from controlled clinical trials is limited, available studies suggest that up to 50% of patients treated with Fumaderm ® achieve at least 75% reduction of their baseline 'psoriasis area and severity index' (PASI) after 12-16 weeks of treatment. [3, 4] The most common side effects during induction therapy are flushing and gastrointestinal side effects such as nausea, vomiting and diarrhea which may lead to treatment discontinuation in as many as 30% of the patients. One major advantage of Fumaderm ® is its excellent efficacy and tolerability during long-term treatment. In long-term studies, 50-70% of the patients experience improvements of ≥ 70% after 1 year of therapy. [5] [6] [7] [8] In Germany, large numbers of responding patients have been treated for several years and patients with successful continuous therapy for 10 or more years are not uncommon. Leukopenia (particularly lymphopenia) system. [6] [7] There is evidence that changes in this system contribute to a decreased translocation of nuclear factor kappa B leading to an inhibition of the expression of proinflammatory cytokines including TNF-α, interleukin (IL)-8 and IL-1β. Through this and other activities, FAEs modulate a variety of events involved in the exaggerated immune response in psoriasis. It has been concluded mostly from in vitro experiments that FAEs mediate the following anti inflammatory, immune-modulatory and anti-proliferative effects: is a concern during long-term FAE treatment. However in 1. Inhibition of the cytokine-induced expression of adhesion contrast to methotrexate (MTX), lymphopenia is usually not molecules such as ICAM-1, VCAM-1 and E-selectin on significant, not associated with signs of immunosuppression dermal fibroblasts [12, 13] and endothelial cells. [14] and is reversible within weeks after cessation of treatment.
2. Suppression of not only the production of T helper type-1 Impairment of renal function has been observed in some and pro-inflammatory mediators such as TNF-α and IFN-γ patients in the days of non-standardized FAE therapy and but enhancement of the formation of cytokines with antiis a very rare event now with Fumaderm ® . Nonetheless, inflammatory properties such as IL-10 and IL-1RA. [15, 16] control of creatinine levels is mandatory during treatment 3. Decrease of the maturation and T helper type-1-inducing with FAEs and therapy should be stopped if increased capacity of dendritic and other antigen presenting cells creatinine levels are noticed. Fumaderm ® is effective in and promotion of apoptosis in these cells; the stimulation patients who can not be successfully treated with either of T helper type-2 cytokine production seems to be less UV phototherapy with or without retinoids or MTX or affected. [17] [18] [19] [20] cyclosporine. [3] There is also evidence for the synergistic 4. Induction of apoptosis not only in antigen presenting effects of the combination of Fumaderm ® with topical cells but in various other immune cells including therapies, especially calcipotriol. [9] activated T cells which is accompanied by a strong induction of the anti-inflammatory stress protein heme PHARMACOKINETICS oxygenase 1 (HO-1).
[21,22]
PHARMACOKINETICS
Little is known about the pharmacokinetics of FAEs.
On the other hand, FAEs have no effects on the production Recent in vitro data suggests that hydrolysis of DMF to of superoxide anions, which are components of the innate the bioactive metabolite MMF occurs rapidly at pH 8 defense against microorganisms. [23] (simulating the alkaline pH found in the small intestines) but not at pH 1, which is the pH found in the stomach.
[10]
USES USES This indicates that hydrolysis of DMF occurs mainly in the small intestine. Most likely, MMF and MEF are then Plaque-type psoriasis absorbed into the blood circulation where they interact There is substantial evidence from at least eight clinical with blood cells. MMF and MEF may also influence studies conducted between 1987 and 2004 mostly in patients inflammatory cells in psoriatic lesions. In humans, serum concentrations of MMF after oral intake reach peak levels within 5-6 hours. MMF is further metabolized to fumaric acid and finally to H 2 O and CO 2 , the latter being eliminated via respiration where it is detectable as early as 80 minutes after oral intake.
[11]
MECHANISM OF ACTION MECHANISM OF ACTION
The major current hypothesis of the pharmacodynamic effect of FAEs is based on the concept that DMF and MMF influence pro-inflammatory signal transduction pathways through modulation of the intracellular redox with severe psoriasis, that monotherapy with FAEs is an effective treatment of this condition.
[4]
Pustular psoriasis
There are a few reports of successful treatment of pustular psoriasis with FAEs. [24, 25] 
Psoriasis capitis
Due to the lack of controlled clinical trials, efficacy of FAEs in this manifestation of psoriasis has not been documented. In clinical experience, FAEs can be helpful in controlling severe cases of psoriasis capitis presenting incomplete response to topical therapy alone. 
Nail psoriasis
This often very-difficult-to-treat manifestation of psoriasis response and the onset of adverse effects. One tablet of Fumaderm initial ® appears to be a reasonable starting dose for a dose-escalation protocol. Dose escalation is continued until a satisfactory clinical response is reached and then the dosage is steadily reduced to an individual maintenance dose. The final dosage may range up to 1-2 g/d (6 tablets of Fumaderm ® ). Most patients treated with fumaric acids require two to four tablets of Fumaderm ® . Dosage is neither related to body weight nor to the activity of the disease. Treatment may be discontinued abruptly as relapse or rebound phenomena do not occur. [4] shows at least some improvement during long-term treatment with FAEs in many patients. [27] However, controlled RECOMMENDA ATION RECOMMEND TIONS trials are not available.
Recommendations for follow-up investigations are given in There are case reports describing successful treatment of levels increase above the normal range.
Uses other than psoriasis
patients with disseminated granuloma annulare with FAEs.
[ 28 31] FAEs may represent a therapeutic option in more severe CONCOMITANT THERAP CONCOMITANT THERAPY cases unresponsive to treatment with PUVA and potent topical corticosteroids.
Currently, a combination of fumaric acids with systemic medication, i.e., cyclosporine or methotrexate is not recommended because of lack of experience. However, the Some authors claim to have observed a positive effect of FAEs additional use of calcipotriol administered topically has been in cutaneous and systemic sarcoidosis. [32, 33] shown to significantly increase the efficacy of FAE treatment with faster resolution of psoriatic lesions than with FAE Necrobiosis lipoidica monotherapy.
[9]
There is data for the treatment of eighteen patients with histopathologically proven necrobiosis lipoidica with FAEs SIDE EFFECTS S SIDE EFFECT according to the standard schedule for psoriasis (see below).
[34]
After a mean treatment period of 7.7 months, a significant Side effects of treatment with FAEs are summarized in Table  decrease in the mean clinical score was observed. The 3. Adverse events during treatment with fumaric acids are improvement remained stable over six months of follow-up. 
DOSAGE DOSAGES
The established treatment regimen of FAEs in psoriasis proposes a gradual increase in dosage according to the schedule depicted in Table 1 . This schedule has been shown to improve gastrointestinal tolerance. [4] In each patient, the final daily dosage needs to be adjusted according to the individual common and are reported in up to two thirds of all patients. [5, 27] The most common side effects are gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and malaise. These signs and symptoms occur primarily within the first few weeks after initiation of treatment and within 90 minutes to German S3-guidelines of psoriasis, evaluation of 13 studies has shown a proportion of 50-70% of patients who achieved PASI 75 improvement within four months of treatment and without any long-term toxicity, immunosuppressive effects or increased risk of infection or malignancy. [4] Tolerance is limited by gastrointestinal side effects and flushing of the skin in about two thirds of the patients. These side effects are dose-dependent and decrease in frequency in the course of treatment. Monitoring of full blood cell count, liver and kidney function as well as urine analysis is necessary. six hours after oral intake of the drug. They last for several Improvement of lesions of psoriasis on fumaric acids may minutes up to half an hour and can be alleviated by intake be accelerated by combination with topical agents such as of tablets with milk. Flushing of the skin is another common calcipotriol.
complaint, ranging from rapid sensation of heat to longlasting facial redness. Improvement of the latter side effect because data for use in these conditions is limited.
[4, 37, 38] 
DRUG INTERACTION DRUG INTERACTIONS
FAEs have no known metabolic interactions with other drugs. Concurrent use of fumaric acids with other drugs having side effects on kidney function should be avoided because of increased toxicity (e.g., methotrexate, cyclosporine, psoralen, immunosuppressive drugs and cytostatics). ) .
